VIJAYA

Vijaya Diagnostic Centre Financial Results

₹1,475.00+0.57%
Market cap
₹15,177 crore
P/E
81.0
P/B
15.86
ROE
19.7%
Dividend yield
0.14%

For the year ended Mar 2022, Vijaya Diagnostic Centre reported revenue of ₹462 crore and net profit of ₹111 crore, against ₹459 crore and ₹85 crore a year earlier.

Vijaya Diagnostic Centre annual profit and loss

Financial years, newest first. TTM = trailing twelve months.

Vijaya Diagnostic Centre annual profit and loss (₹ crore)
ItemMar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue462459548681814857
Expenses259277327408477495
Operating profit204182221273337362
Operating margin %44%40%40%40%41%42%
Other income131217151920
Interest161922253135
Depreciation536257719296
Profit before tax147114159193233251
Tax %25%25%25%26%26%25%
Net profit11185120144173187
EPS (₹)10.758.2911.6114.0116.8118.22
Dividend payout %——————

Source: Company filings (consolidated), in ₹ crore. Data as of 7 October 2026. How this data is compiled.

Vijaya Diagnostic Centre financial results — frequently asked questions

What is Vijaya Diagnostic Centre's annual revenue and net profit?

For the financial year ended Mar 2022, Vijaya Diagnostic Centre's revenue was ₹462 crore and net profit ₹111 crore; net profit rose 30.59% from ₹85 crore in Mar 2023.

How fast has Vijaya Diagnostic Centre grown over three years?

From Mar 2025 to Mar 2022, Vijaya Diagnostic Centre's revenue grew at a compound annual rate of -12.1% and net profit at -8.3%. Past growth does not indicate future results.

What is the EPS of Vijaya Diagnostic Centre?

Annual EPS for Mar 2022 was ₹10.75.

Are these figures consolidated or standalone?

They are consolidated figures as reported by the company, in ₹ crore. Trailing-twelve-month and half-year columns are labelled separately and are not counted as financial years.

Same Data For Peers

Trade Vijaya Diagnostic Centre With ATS

Track VIJAYA live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.

Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.